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OXIDATIVE stress  in  the  lung  is  important  in  the
pathogenesis of  COPD. Published data indicate that
glucocorticoids inhibit blood cells in their capacity to
produce  reactive  oxygen  species  (ROS).  We  investi-
gated the effect of Fluticasone propionate (FP) on the
ROS production capabilities of pulmonary cells. Bron-
choalveolar lavage (BAL) was performed in smoking
COPD patients, before and after a six month, placebo-
controlled treatment with FP. BAL cells were stimu-
lated  with  phorbol  myristrate  acetate  (PMA)  alone,
and together with superoxide dismutase (SOD). From
kinetic  plots  of  ferricytochrome-c  conversion  we
calculated  the  maximal  rate  of  superoxide  produc-
tion:  Vm ax .  We  also  examined  BAL  cell subsets  and
performed correlation analyses on ROS  production
and  relevant  clinical  determinants.  Paired  results
were  obtained  from  6  FP-  and  9  placebo-treated
patients. No significant change of Vm ax was found in
both patient groups. Also BAL cellularity was unchan-
ged.  Correlation  analyses  showed  a  significant
(inverse )  association  of  Vm ax with  the  number  of
cigarettes  smoked  per  day.  We  concluded  that  a
potent  inhaled  glucocorticoid  had  no  effect  on  the
ROS production capability of BAL cells from smoking
COPD patients. Apparently, heavy smoking impaired
the ability of alveolar macrophages to produce ROS,
which was not further decreased by FP.
Key  words:  Reactive  oxygen  species,  Bronchoalveolar
lavage,  Fluticasone  propionate,  Inhaled  glucocorticoid,
Chronic obstructive pulmonary disease, Smoking
Introduction
The  airways  and  alveoli  of  patients  with  chronic
obstructive airways disease (COPD) are invaded with
numerous inflammatory cells, which have the ability
to  produce  reactive  oxygen  species  (ROS).1 It  has
been established that an increased oxidative stress is
one of the major pathogenic mechanisms.2,3 Oxida-
tive stress may occur either by an increased exposure
to  ROS  or  by  a  decreased  capacity  of  the  involved
tissue to neutralise the constantly-emerging produc-
tion of ROS. Both mechanisms seem to be involved in
the development of COPD. The smoking of cigarettes
is clearly related to COPD. Cigarette smoke contains
several molecules, which are ROS by themselves, and
it  also  contains  molecules  and  particulates,  which
generate chemical reactions and inflammation, with
subsequent ROS production.4
A  major  goal  in  the  treatment  of  COPD  is  the
reduction  of  the  number  and/or  the  activity  of
inflammatory  cells.  In  asthma  patients,  glucocor-
ticoids  have  been  applied  successfully  with  this
intention. In the present study, we have investigated if
a potent inhaled glucocorticoid (Fluticasone propio-
nate, FP) could reduce the ROS production in COPD
patients.  We  have  selected  COPD  patients  with
bronchial hyperresponsiveness (BHR) because these
patients  have  an  exaggerated  decline  of  their  lung
function. We hypothesized that inflammation and ROS
production in this subgroup of COPD patients were
severe,  and  could  be  influenced  by  an  inhaled
glucocorticoid. Inflammatory cells were collected by
means  of  bronchoalveolar  lavage  (BAL),  before  and
after treatment with inhaled FP or placebo. Besides
cell  counts,  the  ROS  production  capability  was
determined in vitro. Furthermore, we analyzed the
association of ROS production capability with smok-
ing behaviour, airways obstruction and BHR.
Material and methods
Patients
COPD patients were selected according to the clinical
and  functional  criteria,  which  are  generally
accepted.5 Inclusion  criteria  were:  age  between 40
and 70 years, current smoker, FEV1/iVC ratio £ 70% of
predicted  normal  values  (pred),  reversibility  of
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BHR – defined by a PC20 histamine £ 8 mg/ml – and
negative  skin  tests  for  standard  inhaled  allergens.
Reference  values  were  obtained  from  ECCS  stan-
dards.6 The main exclusion criteria were a history of
asthma  and  recent  respiratory  tract  infection.  Any
anti-inflammatory  drugs,  including  steroids  and
NSAIDs, and theophyllines were discontinued. Poten-
tial candidates for this study were informed about the
negative effects of smoking, and we offered them the
opportunity  to  participate  in  a  smoking-cessation
program. The  Hospital’s  Medical  Ethics  Committee
approved  the  study. Written  informed  consent  was
obtained from all participants.
Design of the intervention study
We  performed  a  double  blind,  placebo-controlled
study  that  lasted  for  six  months.  Patients  were
randomly assigned to either twice-daily 500 m g FP or
placebo, which were delivered via a similar diskhaler.
The start of treatment was immediately after the first
bronchoscopy.  Bronchoscopy  was  repeated  at  the
end of the study. At intervals of four weeks, the study
participants had a check-up.
Bronchoscopy
The  procedure  was  carried  out  according  to  inter-
national  guidelines.7 For  local  anaesthesia  we  used
lidocaine spray and aerosolised oxybuprocaine. The
bronchoscope (Olympus BF 1T10) was advanced into
the  lateral  segment  of  the  middle  lobe,  in  wedge
position.  Lavage  was  performed  successively  with
1´ 40 ml and 4´ 50 ml sterile phosphate-buffered saline
(PBS) solution (Organon Teknika, Boxtel, The Nether-
lands)  at  body  temperature  (37°C)  and  pH  7.4.
Aliquots were aspirated in two siliconized specimen
traps, one for the first ‘bronchoalveolar fraction’ after
40 ml PBS and the second ‘alveolar fraction’ for the
recovery  of  the  4´ 50ml  PBS. The  lavage  fluid  was
transported to the laboratory on ice and processed
immediately. The recovery of the first, bronchoalveo-
lar fraction appeared to be low and insufficient  for
performing the desired experiments.
Processing of BAL fluid
After  measurement  of  volume,  the  BAL  fluid  was
filtered through sterile nylon gauzes and centrifuged
at 400´ g (4°C for 5 min). The cell pellet was washed
in PBS supplemented with 0.5% bovine serum albu-
min. The total cell number in the BAL cell suspension
was counted in a Coulter Counter Model ZM (Coulter
Electronics,  Hialeah,  FL,  USA)  and  viability  was
assessed  by  cellular  exclusion  of  trypan  blue. With
FACScan flow-cytometry (Becton Dickinson, San Jose,
CA,  USA)  we  analyzed  CD3+ T-cells.  Immunocy-
tochemistry  of  cytospins  was  carried  out  with  the
APAAP  (alkaline  phosp-hatase  anti-alkaline  phospha-
tase)  method  with  monoclonal  antibodies  CD68
(alveolar macrophages), CD15 (VIM-D5, neutrophils),
and BMK–13 (eosinophils). Two independent obser-
vers counted at least 300 cells in each cytospin.
Superoxide production assay
ROS production of BAL cells was determined by the
kinetic  microplate  assay  of  superoxide  dismutase
(SOD)-inhibitable ferricytochrome-c (0.16 mM horse
heart  cyto-chrome-c,  Sigma)  reduction  in  a  96-well
microplate (Falcon 3072, Becton Bickinson, Lincoln
Park, NJ). The cells, at a density of 1´ 105/well, were
stimulated, in the absence and presence of SOD, with
8 nM  and  80 nM  phorbol  12-myristate  13-acetate
(PMA) at 37°C. At 18 seconds intervals the change in
absorbance  at  550nm  (1nm  bandwith)  was  read
during  20 min  in  a Thermomax  microplate  reader
(Molecular Devices, Sopachem, Lunteren, The Nether-
lands), using 540 nm (10nm bandwith) as a reference
wavelength.  All  measurements  were  performed  in
duplicate. Using the software programme SOFTmax
PRO  the  maximum  velocity  (Vmax )  of  ferricyto-
chrome-c  reduction  was  determined  by  calculating
the first derivative of the absorbance time course in
each well, and next expressed as nmol of superoxide/
min/106 cells,  using  the  difference  in  Vmax in  the
presence  and  absence  of  SOD,  the  reduced  minus
oxidized  cytochrome-c  extinction  coefficient  of
21.1 mM–1 cm–1, and the empirically determined light
path length. Since we found the Vmax upon stimula-
tion  with  80nM  PMA  did  not  increase  further  as
compared  to  8 nM  PMA,  apparently  the  cells  were
already  maximally  stimulated  at  the  lowest  PMA
concentration. Therefore,  we  present  these  data  as
the  mean  and  do  not  refer  to  the  PMA
concentration.
Statistical analysis
Pre-  and  post-intervention  data  were  tested  for  sig-
nificant difference with the paired t-test. Differences
between patient groups were tested with either the
(unpaired) Student t-test or the Mann–Whitney test,
depending  upon  distribution  of  data.  Correlation
studies were performed with the Spearman rank test.
Statistical significance was considered at p<0.05.
Results
From the  initial  23  participants  in  the  intervention
study, paired results were obtained from 6 FP patients
and  from  9  patients  with  placebo. The  reasons  for
missing  paired  data  were  insufficient  recovery  of
either BAL fluid or BAL cells. The patient character-
istics (n=15), listed in Table 1, show that on average
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airways  disease  and  severe  BHR.  Compliance  with
study  medication  was  high:  the  percentage  of
returned used blisters was 92.5 in the FP and 92.7 in
the placebo group.
Differences in baseline characteristics between the
FP  and  the  placebo  group  were  not  statistically
significant. In the placebo group, mean FEV1 declined
from 68.5%pred at the start of the trial to 52.0%pred
after  6  months.  However,  lung  function  remained
unchanged  in  the  FP  group  (mean  FEV1:  72.4  and
69.1%pred,  respectively). This  treatment  effect  was
statistically significant, and considered as a beneficial
effect of FP treatment.
Immunocytology
Mean total cell number of the BAL at the start of the
trial  was  53.0´ 106 for  FP  treated  patients  and
45.3´ 106 in  the  placebo  group  (Table  2).  Small
changes were noticed in the BAL cell numbers at the
end of the trial, which were not significant (Table 2).
The percentages of fluid recovery, cell viability and
cell  types  were  not  statistically  different  between
both patient groups, before intervention, and did not
change  significantly  after  6  months  of  intervention
(Table 2). The low number of eosinophils  indicates
that COPD was stable in nature.
ROS production capability
Figure 1 shows Vmax of the patients from the FP and
the  placebo  group,  before  and  after  intervention.
Vmax ranged from 0.076  to 0.753  (mean 0.35)nmol
superoxide/min/106 cells in the FP treated patients,
and from 0.06 to 0.67 (mean 0.303) in the placebo
group. Statistical analysis showed that there were no
significant changes after FP or placebo.
Association of Vmax with airways obstruction,
BHR and smoking status
There were no significant correlations between pre-
treatment Vmax on the one hand, and FEV1 and PC20
on the other. However, the actual number of cigar-
ettes  smoked  per  day  correlated  significantly  with
pre-treatment Vmax (Fig. 2, R=–0.67, p=0.007, Spear-
man rank test). There was no significant correlation of
Vmax and packyears of smoking.
Discussion
In  this  double  blind,  placebo  controlled  trial,  we
observed  no  significant  effect  of  a  potent  inhaled
glucocorticoid  on  the  ROS  production  capability
(Vmax ) of BAL cells derived from a subgroup of COPD
patients, namely those with bronchial hyperrespon-
siveness.  At  first  glance,  this  result  appears  to  be
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Table 1. Patient characteristics (mean ±SD)
Fluticasone propionate Placebo
N 6 9
Age 56 ± 7 57 ± 9
Cigarettes/day 17 ± 8 15 ± 5
Packyears 25 ± 12 27 ± 10
FEV1%pred 72 ± 12 68 ± 13
FEV1 reversibility 4.6 ± 2.4 5.3 ± 2.4
PC20 histamine 3.3 ± 3.2 0.8 ± 0.6





Fluid recovery, % 60 ± 13 62 ± 11 54 ± 16 51 ± 19
Cell number, 3 10
6 53 ± 13.5 59 ± 31 45.3 ± 22.7 36.4 ± 18
Cell viability, % 62 ± 12 66 ± 12 70 ± 13 67 ± 12
CD68
+ macrophages, % 95 ± 3 95 ± 4 95 ± 4 91 ± 5
CD15
+ granulocytes, % 2.4 ± 2.8 1.9 ± 1.2 3.1 ± 2.8 4.2 ± 7.5
BMK13
+ eosinophils, % 0.4 ± 0.3 0.8 ± 0.5 0.4 ± 0.3 0.8 ± 1.0
CD3
+ T-cells, % 2.0 ± 2.9 0.7 ± 0.9 3.0 ± 2.9 3.0 ± 6.5
FIG. 1. Results of the superoxide production assay.
Vmax:  maximum  velocity  of  reactive  oxygen  species  pro-
duction,nmol/min/10
6 cells; FP: Fluticasone propionate; Plac:
placebo; pre: pre-intervention; post: post-intervention.related to the absence of a decrease in the number of
inflammatory cells in the BAL. Our correlation studies
indicated that actual smoking status is an important
confounding factor. With increasing number of cigar-
ettes smoked per day, Vmax decreases.
As there has not been published a similar study in
COPD patients before, we compared our results with
studies concerning the effects of glucocorticoids on
ROS production capacity of blood-derived cells, and
with studies concerning the effect of smoking.
In one study, the superoxide production by PMA-
stimulated  blood  granulocytes,  taken  from  18  mis-
cellaneous patients on oral glucocorticoid treatment,
was  decreased  as  compared  to  healthy  controls.8
Superoxide  production  by  blood  granulocytes  of
patients with emphysema was decreased after in vivo
prednisolone  treatment.9 However,  dexamethasone,
both in vitro and in vivo, did not alter the sponta-
neous superoxide release of blood granulocytes from
healthy volunteers.10
The  reported  studies  concerning  the  effect  of
smoking on ROS production capability are not con-
sistent.  Alveolar  macrophages  (AM)  from  healthy
smokers  produced  more  superoxide  than AM  from
nonsmoking  control  subjects.11–13 Exposure  to
tobacco  smoke  in  vitro increased  the  oxidative
metabolism  of  AM,14 while  it  reduced  superoxide
generation  by  blood  granulocytes.15 Hoidal  et  al.
used  almost  the  same  lavage  method  as  in  our
study,  and  compared  young  asymptomatic  smokers
with  nonsmokers.11 They  reported  that  BAL  cells
from  smokers,  stimulated  with  PMA,  produced  on
average  1.93 nmol  ROS/min/106 cells,  while  BAL
cells  from  nonsmokers  produced  0.945 nmol  ROS/
min/106 cells.  We  found  an  average  (pre-interven-
tion)  ROS  production  of  0.322 nmol/min/106 cells
(n=15). The  low  ROS  production  capability  in  our
study  could  either  be  due  to  patient  selection
(COPD),  the  presence  of  BHR,  different  BAL  cell
counts or to smoking. ROS production by BAL cells
from  smokers  without  COPD  was  not  different
from  smokers  with  COPD.16 Therefore,  the  diag-
nosis  of  COPD  seems  to  be  unimportant.  Fur-
thermore,  since  the  level  of  PC20  was  not  sig-
nificantly correlated with Vmax , and the cell profile
in  BAL  resembles the reported  findings  in ‘average’
COPD patients and smokers, the first three options
are  not  likely.  However,  our  correlation  analyses
indicate that cigarette smoking influences ROS pro-
duction  capability. A  possible  explanation  could  be
that  viable  macrophages  lose  their  ability  to
release superoxide after repeated stimulation.17 This
was  attributed  to  ligand-induced  desensitisation  of
specific  receptors.  This  phenomenon  might  also
have  occurred  in  our  heavy  smoking  COPD
patients.
In conclusion, the BAL cells from smoking COPD
patients  with  BHR,  consisting  mainly  of  alveolar
macrophages, have a low ROS production capability.
This was not further decreased by in vivo exposure to
a potent inhaled glucocorticoid. The low ROS produc-
tion capability might be one of the causative mecha-
nisms  of  the  increased  susceptibility  to  respiratory
tract  infections  and  the  increased  frequency  of
bacterial colonisation of the airways in these COPD
patients.
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